This peptide coach's claims need serious fact-checking

What did @rahulmodifit actually say?

The creator walked through a full retatrutide reconstitution and subcutaneous injection tutorial, including dosing math. He said he's running a retatrutide cycle at "2 milligrams a week split into two doses, 1 milligram per injection," using 2 mL of bacteriostatic water in an 11 mg vial, and drawing to "18.2 or roughly 18 units" on an insulin syringe. He also warned viewers not to shake the vial because "these compounds are fragile" and to angle the needle against the glass when adding reconstitution water. The video is, at its core, a how-to guide for self-injecting a peptide that has never been approved for human use outside of clinical trials.

That last point matters more than any tip about needle angle. Retatrutide is not a peptide supplement. It is an investigational triple agonist drug (GIP, GLP-1, glucagon receptors) developed by Eli Lilly, currently in Phase 3 trials. What he's injecting came from a gray-market peptide vendor, not a pharmacy.

Does the science back this up?

The pharmacology of retatrutide is real and the early clinical data is genuinely striking. But none of that validates self-injection from an unregulated supplier.

The Phase 2 trial published by Jastreboff et al. (2023, New England Journal of Medicine) showed dose-dependent weight loss up to 24.2% body weight over 48 weeks in adults with obesity, which is why this compound spread fast on social media. The mechanism, simultaneous agonism at GIP, GLP-1, and glucagon receptors, is pharmacologically distinct from semaglutide or tirzepatide and is not fully characterized for long-term safety in humans. Adverse events in the trial included significant rates of nausea, vomiting, and dose-dependent heart rate increases. The trial used rigorously controlled dosing titration schedules, pharmaceutical-grade drug, and regular clinical monitoring. None of those conditions exist in a TikTok tutorial.

His reconstitution math appears correct based on the numbers he gives. The technique advice about not shooting water directly into lyophilized powder is consistent with standard compounding guidance. The science on peptide degradation from aggressive agitation is legitimate. But correct technique does not make the source material safe or legal.

What did they get wrong (or right)?

Credit where it's due: his reconstitution technique is largely sound. Bacteriostatic water is the correct diluent for multi-dose peptide vials. The advice to angle the needle against the glass wall and avoid direct powder disruption is appropriate. The math he walks through, using a peptide calculator to convert micrograms to syringe units, is coherent and something many viewers genuinely don't understand.

What he got wrong, or rather what he omitted entirely, is significant. He never tells viewers where this retatrutide came from or whether it has been tested for purity and potency. Research-grade peptides from gray-market vendors vary dramatically in actual content. A 2022 analysis by Bannwarth et al. found that a substantial proportion of peptides purchased from online suppliers contained incorrect concentrations or contaminants. He also presents a specific dose as though it's a reasonable starting point, when the Phase 2 trial used a structured titration from 0.5 mg, not 1 mg injections from week one. Starting at 1 mg without titration meaningfully increases GI adverse event risk. He says nothing about this.

What should you actually know?

Retatrutide is not legally available as a compounded or research peptide in the United States. It is an Eli Lilly investigational drug under active Phase 3 trials. Vendors selling it as a "peptide" are operating outside FDA oversight, and the product has no verified identity, sterility, or potency guarantee. This is not a technicality. Injecting an unverified substance subcutaneously carries real infection and dosing error risk.

The broader issue is that this video teaches injection technique to a general audience using a compound with no approved human dosing protocol. The Jastreboff 2023 NEJM data is exciting, but it was generated under controlled clinical conditions with pharmaceutical-grade drug and active safety monitoring. Replicating the compound name does not replicate those conditions.

• If you're interested in GLP-1 or related mechanisms for weight management, FDA-approved options exist and can be prescribed through regulated telehealth.
• No compounded version of retatrutide has FDA authorization. Any vendor claiming otherwise is misrepresenting the product.
• The correct titration schedule, adverse event profile, and contraindications for retatrutide are still being established in Phase 3 trials. There is no established safe self-administration protocol.